Xiaofeng Lan
Biographic Data
| ID | 7662815 |
|---|---|
| NAME | Xiaofeng Lan |
| GIVEN NAMES | Xiaofeng |
| FAMILY NAME | Lan |
| SIGNATURE | LAN X |
| AFFILIATIONS | Guangzhou Medical University |
| ORCID | 0000-0002-7042-084X |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression
Our exploratory, post-hoc analysis of an open-label, single-arm study suggests that patients with depression and a higher baseline BMI may experience greater reductions in depressive symptoms compared with those with a lower baseline BMI after receiving six ketamine infusions
The core inflammatory factors in patients with major depressive disorder
IL-1β is the central inflammatory factor in the network, and there is heterogeneity in the core inflammatory factor of MDD with specific depressive dimension symptoms as the main manifestation. In conclusion, inflammatory factors and their links should be prioritized in future theoretical models of MDD and may provide new research targets for MDD intervention and treatment
Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation
Depressive symptoms severity and processing speed performance partially mediated improvements in suicidal ideation after repeated ketamine infusions in persons with unipolar or bipolar depressive disorder
Plasma Vegf Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation
This preliminary finding does not support a role for VEGF in the antisuicidal effects of serial ketamine treatments in individuals with depression and suicidal ideation. Further research is needed to confirm and expand these findings
Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients
A significant and rapid improvement in depressive symptoms was observed in patients with depression and pain after ketamine treatment. Ketamine may be a novel and promising antidepressant preferentially for the therapy of depression with severe pain
Association of Vegf With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression
Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD). Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery-Åsberg Depr…
No prominent works on this page.
Association of Vegf With Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Treatment-Refractory Depression
Objectives: To first explore the role of plasma vascular endothelial growth factor (VEGF) concentrations in ketamine's antianhedonic effects, focusing on Chinese patients with treatment-refractory depression (TRD). Methods: Seventy-eight patients with treatment-refractory major depressive disorder (MDD) or bipolar disorder (BD) were treated with six ketamine infusions (0.5 mg/kg). Levels of anhedonia were measured using the Montgomery-Åsberg Depr…
Cognitive Function Mediates the Anti-suicide Effect of Repeated Intravenous Ketamine in Adult Patients With Suicidal Ideation
Depressive symptoms severity and processing speed performance partially mediated improvements in suicidal ideation after repeated ketamine infusions in persons with unipolar or bipolar depressive disorder
Plasma Vegf Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation
This preliminary finding does not support a role for VEGF in the antisuicidal effects of serial ketamine treatments in individuals with depression and suicidal ideation. Further research is needed to confirm and expand these findings
Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients
A significant and rapid improvement in depressive symptoms was observed in patients with depression and pain after ketamine treatment. Ketamine may be a novel and promising antidepressant preferentially for the therapy of depression with severe pain
The core inflammatory factors in patients with major depressive disorder
IL-1β is the central inflammatory factor in the network, and there is heterogeneity in the core inflammatory factor of MDD with specific depressive dimension symptoms as the main manifestation. In conclusion, inflammatory factors and their links should be prioritized in future theoretical models of MDD and may provide new research targets for MDD intervention and treatment
Body mass index is associated with the antidepressant effects of intravenous ketamine in patients with depression
Our exploratory, post-hoc analysis of an open-label, single-arm study suggests that patients with depression and a higher baseline BMI may experience greater reductions in depressive symptoms compared with those with a lower baseline BMI after receiving six ketamine infusions
Medicine (6 works) · Tryptophan and brain disorders (6 works) · Ketamine (5 works) · Major depressive disorder (5 works) · Treatment of Major Depression (5 works) · Depression (economics (4 works) · Internal Medicine (4 works) · Psychiatry (4 works) · Psychology (4 works) · Anesthesia (3 works)